Weightless Medical LLC dba WeightCare

Warning LetterOpen

United StatesIssued Feb 20, 2026Center for Drug Evaluation and Research (CDER)

View Letter

Source: FDA, published letter. FDA published this warning letter; View Letter opens FDA's copy.

Violations2

Issue DateFeb 20, 2026

Product TypeDrugs

StatusOpen

Letter Details

Firm: Weightless Medical LLC dba WeightCare
Location: United States
FEI Number: N/A
Country: United States
Issue Date: February 20, 2026
Issuing Office: Center for Drug Evaluation and Research (CDER)
Product Type: Drugs
Status: Open

Summary

Weightless Medical LLC dba WeightCare was cited for misbranding compounded semaglutide and tirzepatide drug products offered on its website. The company falsely represented itself as the compounder of these drugs by displaying the "WeightCare" name on product labels when it was not actually manufacturing them, violating sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act. The misbranded products were introduced into interstate commerce through the company's website, constituting prohibited acts under the FDCA. The FDA conducted its review of the company's website content in December 2025 and issued the warning letter in February 2026.

Weightless Medical LLC dba WeightCare FDA Warning Letter, February 20, 2026